Renovorx Inc Revenue Growth Rates (RNXT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Renovorx Inc   (NASDAQ: RNXT)
 

RNXT's Revenue Growth by Quarter and Year

Renovorx Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNXT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.91
1st Quarter March 0.56
FY 1.47





RNXT Revenue second quarter 2026 Y/Y Growth Comment
Renovorx Inc achieved in the second quarter 2026, above Company average Revenue surge of 116.43% year on year, to $ 0.91 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue growth. While Renovorx Inc ' s Revenue doubling of 116.43% ranks overall at the positon no. 808 in the second quarter 2026.


RNXT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 500 % - -
3rd Quarter September - - - -
2nd Quarter June 116.43 % - - -
1st Quarter March 180 % - - -
FY   - 2725 % - -

Financial Statements
Renovorx Inc 's second quarter 2026 Revenue $ 0.91 millions RNXT's Income Statement
Renovorx Inc 's second quarter 2025 Revenue $ 0.42 millions Quarterly RNXT's Income Statement


RNXT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -11.11 % - -
3rd Quarter September - -35.71 % - -
2nd Quarter June 62.32 % 110 % - -
1st Quarter March 133.33 % 400 % - -
FY (Year on Year)   - 2725 % - -


Back to RNXT Growth rate Comparisons >> Back to RNXT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #171
Overall #808

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #171
Overall #808
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Renovorx Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
358.14 % 103.81 % -36.97 %
(Mar 31 2025)  


RNXT's II. Quarter Q/Q Revenue Comment
Renovorx Inc achieved in the II. Quarter 2026 below company average Revenue jump of 62.32% quarter on quarter, to $ 0.91 millions.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Renovorx Inc 's Revenue growth quarter on quarter, overall rank is 196.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #57
Overall #196
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #57
Overall #196
Revenue Q/Q Growth Statistics
High Average Low
358.14 % 103.81 % -36.97 %
(Mar 31 2025)  


RNXT's II. Quarter Q/Q Revenue Comment
Renovorx Inc achieved in the II. Quarter 2026 below company average Revenue jump of 62.32% quarter on quarter, to $ 0.91 millions.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Renovorx Inc 's Revenue growth quarter on quarter, overall rank is 196.


Renovorx Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1.98 $ 1.49 $ 1.12 $ 0.93 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 32.71 % 32.59 % 21.01 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 808 # 652 # 571 # 0 # 0


Cumulative Revenue growth Comment
Renovorx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 116.43% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026.
Renovorx Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Renovorx Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 32.71 % from $1.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 32.71 % increase from $1.49 millions in the period from Mar 31 2026 to Jun 30 2025.

Renovorx Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 66
Sector # 171
S&P 500 # 808
Cumulative Revenue growth Comment
Renovorx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 116.43% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026.
Renovorx Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Renovorx Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 32.71 % from $1.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 32.71 % increase from $1.49 millions in the period from Mar 31 2026 to Jun 30 2025.

Renovorx Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 66
Sector # 171
S&P 500 # 808




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RNXT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions


About Renovorx Inc Revenue Growth Rates (RNXT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Renovorx Inc (CIK 1574094).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349190
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Renovorx Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.